FiercePharma

New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia

Results served as basis for regulatory filing with U.S. Food and Drug Administration and designation as Priority Review TITUSVILLE, N.J., March 29, 2015 /PRNewswire/ -- Three-month paliperidone ...
Monthly Prescribing Reference

Erzofri Approved for Schizophrenia, Schizoaffective Disorder

Erzofri is an atypical antipsychotic that is administered once a month as an intramuscular injection. The Food and Drug Administration (FDA) has approved Erzofri ® (paliperidone palmitate) ...
Healthline

All About Invega Sustenna

Invega Sustenna (paliperidone palmitate) is a prescription drug that’s used to treat schizophrenia and schizoaffective disorder. Invega Sustenna is given as an injection into your muscle by a ...
FiercePharma

Study Published in The Journal of Clinical Psychiatry Shows INVEGA SUSTENNA® Effective Six Months Longer Than Common Oral Antipsychotics in Treatment of Schizophrenia

Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study published ...
News Medical

Invega Sustenna

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA SUSTENNA contains the active ingredient paliperidone palmitate.